These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 7144293)
21. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039 [TBL] [Abstract][Full Text] [Related]
22. Melphalan and its role in the management of patients with multiple myeloma. Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453 [TBL] [Abstract][Full Text] [Related]
23. Acute plasma cell leukemia. Emergence of anaplastic myeloma shortly after intravenous alkylating agents. A case record. Bernardeschi P; Bonechi I Haematologica; 1989; 74(3):331-2. PubMed ID: 2511107 [No Abstract] [Full Text] [Related]
24. Multiple myeloma terminating in acute leukemia: report of two cases and review of the literature. Martínez-Poventud G; Fernández AC; Vélez-García E Bol Asoc Med P R; 1985 Oct; 77(10):419-21. PubMed ID: 3865657 [No Abstract] [Full Text] [Related]
25. [Acute leukemia in a case of multiple myeloma]. van Hove W; Hamers J Ned Tijdschr Geneeskd; 1973 Sep; 117(39):1462-5. PubMed ID: 4522766 [No Abstract] [Full Text] [Related]
26. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495 [TBL] [Abstract][Full Text] [Related]
27. [Secondary myeloid/natural killer cell acute leukemia appeared in multiple myeloma treated with melphalan]. Kaya H; Nakamura S; Yamazaki H; Kumabashiri I; Ohtake S; Matsuda T Rinsho Ketsueki; 1995 Jul; 36(7):682-6. PubMed ID: 7563597 [TBL] [Abstract][Full Text] [Related]
28. Long-term survival in multiple myeloma. Kyle RA N Engl J Med; 1983 Feb; 308(6):314-6. PubMed ID: 6823231 [No Abstract] [Full Text] [Related]
29. Derivative (1;7)(q10;p10) in multiple myeloma. A sign of therapy-related hidden myelodysplastic syndrome. Ishii Y; Hsiao HH; Sashida G; Ito Y; Miyazawa K; Kodama A; Ohyashiki JH; Ohyashiki K Cancer Genet Cytogenet; 2006 Jun; 167(2):131-7. PubMed ID: 16737912 [TBL] [Abstract][Full Text] [Related]
30. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. Offidani M; Marconi M; Corvatta L; Olivieri A; Catarini M; Leoni P Haematologica; 2003 Dec; 88(12):1432-3. PubMed ID: 14688003 [No Abstract] [Full Text] [Related]
31. The cyclic use of multiple alkylating agents in multiple myeloma. Harley JB; Ramanan SV; Kim I; Thiagarajan PV; Chen JH; Gomez R; Koppel D; Hyde F; Gustke S; Krall J W V Med J; 1972 Jan; 68(1):1-3. PubMed ID: 4500402 [No Abstract] [Full Text] [Related]
32. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation. Hájek R; Adam Z; Vásová I; Král Z Acta Med Austriaca; 1996; 23(3):85-91. PubMed ID: 8798281 [TBL] [Abstract][Full Text] [Related]
34. [Four cases of therapy-related leukemia in multiple myeloma]. Natori K; Izumi H; Kaneko K; Ishihara S; Nagase D; Fujimoto Y; Kato M; Umeda M; Kuraishi Y Gan To Kagaku Ryoho; 2007 Jan; 34(1):121-4. PubMed ID: 17220686 [TBL] [Abstract][Full Text] [Related]
35. Cryotherapy for the prevention of high-dose melphalan-induced oral mucositis. Mori T; Aisa Y; Yamazaki R; Mihara A; Ikeda Y; Okamoto S Bone Marrow Transplant; 2006 Nov; 38(9):637-8. PubMed ID: 16953203 [No Abstract] [Full Text] [Related]
36. A singular case of multiple myeloma and primary biliary cirrhosis strictly associated in pathogenesis and response to alkylating therapy. Lazzaro A; Bernuzzi P; Arcari A; Bertè R; Moroni FC; Trabacchi E; Vallisa D; Cavanna L Am J Hematol; 2006 Jul; 81(7):557. PubMed ID: 16755555 [No Abstract] [Full Text] [Related]
37. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure. Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285 [TBL] [Abstract][Full Text] [Related]
38. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803 [TBL] [Abstract][Full Text] [Related]
39. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT; J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703 [TBL] [Abstract][Full Text] [Related]
40. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]